Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

ADAM10 Sheddase Activity is a Potential Lung-Cancer Biomarker.

Yoneyama T, Gorry M, Sobo-Vujanovic A, Lin Y, Vujanovic L, Gaither-Davis A, Moss ML, Miller MA, Griffith LG, Lauffenburger DA, Stabile LP, Herman J, Vujanovic NL.

J Cancer. 2018 Jun 23;9(14):2559-2570. doi: 10.7150/jca.24601. eCollection 2018.

2.

Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates.

Yoneyama T, Gorry M, Miller MA, Gaither-Davis A, Lin Y, Moss ML, Griffith LG, Lauffenburger DA, Stabile LP, Herman JG, Vujanovic NL.

J Cancer. 2017 Oct 23;8(19):3916-3932. doi: 10.7150/jca.20779. eCollection 2017.

3.

Soluble TNF Regulates TACE via AP-2α Transcription Factor in Mouse Dendritic Cells.

Ge L, Vujanovic NL.

J Immunol. 2017 Jan 1;198(1):417-427. Epub 2016 Nov 16.

4.

Inhibition of Soluble Tumor Necrosis Factor Prevents Chemically Induced Carcinogenesis in Mice.

Sobo-Vujanovic A, Vujanovic L, DeLeo AB, Concha-Benavente F, Ferris RL, Lin Y, Vujanovic NL.

Cancer Immunol Res. 2016 May;4(5):441-51. doi: 10.1158/2326-6066.CIR-15-0104. Epub 2016 Feb 19.

5.

Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells.

Sobo-Vujanovic A, Munich S, Vujanovic NL.

Cell Immunol. 2014 May-Jun;289(1-2):119-27. doi: 10.1016/j.cellimm.2014.03.016. Epub 2014 Apr 8.

6.

Dendritic cell exosomes directly kill tumor cells and activate natural killer cells via TNF superfamily ligands.

Munich S, Sobo-Vujanovic A, Buchser WJ, Beer-Stolz D, Vujanovic NL.

Oncoimmunology. 2012 Oct 1;1(7):1074-1083.

7.

Adenovirus-engineered human dendritic cells induce natural killer cell chemotaxis via CXCL8/IL-8 and CXCL10/IP-10.

Vujanovic L, Ballard W, Thorne SH, Vujanovic NL, Butterfield LH.

Oncoimmunology. 2012 Jul 1;1(4):448-457.

8.

Suppression of natural killer-cell and dendritic-cell apoptotic tumoricidal activity in patients with head and neck cancer.

Baskic D, Vujanovic L, Arsenijevic N, Whiteside TL, Myers EN, Vujanovic NL.

Head Neck. 2013 Mar;35(3):388-98. doi: 10.1002/hed.22968. Epub 2012 Apr 5.

9.

Acupuncture May Stimulate Anticancer Immunity via Activation of Natural Killer Cells.

Johnston MF, Ortiz Sánchez E, Vujanovic NL, Li W.

Evid Based Complement Alternat Med. 2011;2011:481625. doi: 10.1093/ecam/nep236. Epub 2011 Mar 10.

10.

Role of TNF superfamily ligands in innate immunity.

Vujanovic NL.

Immunol Res. 2011 Aug;50(2-3):159-74. doi: 10.1007/s12026-011-8228-8. Review.

PMID:
21717067
11.

Virally infected and matured human dendritic cells activate natural killer cells via cooperative activity of plasma membrane-bound TNF and IL-15.

Vujanovic L, Szymkowski DE, Alber S, Watkins SC, Vujanovic NL, Butterfield LH.

Blood. 2010 Jul 29;116(4):575-83. doi: 10.1182/blood-2009-08-240325. Epub 2010 Apr 29.

12.

Sheddase activity of tumor necrosis factor-alpha converting enzyme is increased and prognostically valuable in head and neck cancer.

Ge L, Baskic D, Basse P, Vujanovic L, Unlu S, Yoneyama T, Vujanovic A, Han J, Bankovic D, Szczepanski MJ, Hunt JL, Herberman RB, Gollin SM, Ferris RL, Whiteside TL, Myers EN, Vujanovic NL.

Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2913-22. doi: 10.1158/1055-9965.EPI-08-0898. Epub 2009 Oct 20.

13.

The endothelial cell-produced antiangiogenic cytokine vascular endothelial growth inhibitor induces dendritic cell maturation.

Tian F, Grimaldo S, Fujita M, Cutts J, Vujanovic NL, Li LY.

J Immunol. 2007 Sep 15;179(6):3742-51. Erratum in: J Immunol. 2007 Nov 1;179(9):6369. Fugita, Mitsugu [corrected to Fujita, Mitsugu].

14.

Essential role of the TNF-TNFR2 cognate interaction in mouse dendritic cell-natural killer cell crosstalk.

Xu J, Chakrabarti AK, Tan JL, Ge L, Gambotto A, Vujanovic NL.

Blood. 2007 Apr 15;109(8):3333-41. Epub 2006 Dec 12.

15.

Dendritic cells and natural killer cells interact via multiple TNF family molecules.

Makarenkova V, Chakrabarti AK, Liberatore JA, Popovic P, Lu G, Watkins S, Vujanovic NL.

J Leukoc Biol. 2005 Mar;77(3):408-13. Epub 2004 Dec 16.

PMID:
15604121
16.

A novel epitope of N-CAM defines precursors of human adherent NK cells.

Li S, Xu J, Makarenkova VP, Tjandrawan T, Vakkila J, Reichert T, Gooding W, Lagenaur CF, Achim CL, Chambers WH, Herberman RB, Whiteside TL, Vujanovic NL.

J Leukoc Biol. 2004 Dec;76(6):1187-99. Epub 2004 Sep 8.

PMID:
15356097
17.

Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.

Tatsumi T, Huang J, Gooding WE, Gambotto A, Robbins PD, Vujanovic NL, Alber SM, Watkins SC, Okada H, Storkus WJ.

Cancer Res. 2003 Oct 1;63(19):6378-86.

18.

Role of TNF family ligands in antitumor activity of natural killer cells.

Vujanovic NL.

Int Rev Immunol. 2001 Jun;20(3-4):415-37. Review.

PMID:
11878511
19.
20.

Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway.

Janjic BM, Lu G, Pimenov A, Whiteside TL, Storkus WJ, Vujanovic NL.

J Immunol. 2002 Feb 15;168(4):1823-30.

21.

Blood monocytes and tumor-associated macrophages in human cancer: differences in activation levels.

Baskic D, Acimovic L, Samardzic G, Vujanovic NL, Arsenijevic NN.

Neoplasma. 2001;48(3):169-74.

PMID:
11583284
22.

Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay.

Wahlberg BJ, Burholt DR, Kornblith P, Richards TJ, Bruffsky A, Herberman RB, Vujanovic NL.

J Immunol Methods. 2001 Jul 1;253(1-2):69-81.

PMID:
11384670
23.

Inhibition of apoptosis in human tumour cells by the tumour-associated serpin, SCC antigen-1.

Suminami Y, Nagashima S, Vujanovic NL, Hirabayashi K, Kato H, Whiteside TL.

Br J Cancer. 2000 Feb;82(4):981-9.

24.

Constitutive expression and role of the TNF family ligands in apoptotic killing of tumor cells by human NK cells.

Kashii Y, Giorda R, Herberman RB, Whiteside TL, Vujanovic NL.

J Immunol. 1999 Nov 15;163(10):5358-66.

25.

Rat NKR-P1+ CD3+ T cells: selective proliferation in interleukin-2, diverse T-cell-receptor-Vbeta repertoire and polarized interferon-gamma expression.

Badovinac V, Boggiano C, Trajković V, Frey AB, Vujanović NL, Gold DP, Mostarica-Stojković M, Vukmanović S.

Immunology. 1998 Sep;95(1):117-25.

26.
27.

Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.

Whiteside TL, Sung MW, Nagashima S, Chikamatsu K, Okada K, Vujanovic NL.

Clin Cancer Res. 1998 May;4(5):1135-45.

28.

Natural killer cells and tumor therapy.

Whiteside TL, Vujanovic NL, Herberman RB.

Curr Top Microbiol Immunol. 1998;230:221-44. Review.

PMID:
9586358
29.

Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells.

Lang S, Vujanovic NL, Wollenberg B, Whiteside TL.

Eur J Immunol. 1998 Mar;28(3):780-6.

30.

The in vivo effect of hepatotrophic factors augmenter of liver regeneration, hepatocyte growth factor, and insulin-like growth factor-II on liver natural killer cell functions.

Francavilla A, Vujanovic NL, Polimeno L, Azzarone A, Iacobellis A, Deleo A, Hagiya M, Whiteside TL, Starzl TE.

Hepatology. 1997 Feb;25(2):411-5.

31.

Nonsecretory apoptotic killing by human NK cells.

Vujanovic NL, Nagashima S, Herberman RB, Whiteside TL.

J Immunol. 1996 Aug 1;157(3):1117-26.

PMID:
8757616
32.

Antitumor Functions of Natural Killer Cells and Control of Metastases

Vujanovic NL, Basse P, Herberman RB, Whiteside TL.

Methods. 1996 Apr;9(2):394-408.

PMID:
8812692
33.

Elimination of established liver metastases by human interleukin 2-activated natural killer cells after locoregional or systemic adoptive transfer.

Okada K, Nannmark U, Vujanovic NL, Watkins S, Basse P, Herberman RB, Whiteside TL.

Cancer Res. 1996 Apr 1;56(7):1599-608.

34.

Changes of liver-resident NK cells during liver regeneration in rats.

Vujanovic NL, Polimeno L, Azzarone A, Francavilla A, Chambers WH, Starzl TE, Herberman RB, Whiteside TL.

J Immunol. 1995 Jun 15;154(12):6324-38.

PMID:
7759871
35.

Antitumor activities of subsets of human IL-2-activated natural killer cells in solid tissues.

Vujanovic NL, Yasumura S, Hirabayashi H, Lin WC, Watkins S, Herberman RB, Whiteside TL.

J Immunol. 1995 Jan 1;154(1):281-9.

PMID:
7995947
36.

Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.

Yasumura S, Lin WC, Hirabayashi H, Vujanovic NL, Herberman RB, Whiteside TL.

Cancer Res. 1994 Jul 15;54(14):3808-16.

37.

Phenotypic and functional characteristics of human A-NK cells.

Vujanovic NL, Whiteside TL.

Immunol Ser. 1994;61:41-54. No abstract available.

PMID:
8011755
38.

Distinct phenotypic and functional characteristics of human natural killer cells obtained by rapid interleukin 2-induced adherence to plastic.

Vujanovic NL, Rabinowich H, Lee YJ, Jost L, Herberman RB, Whiteside TL.

Cell Immunol. 1993 Oct 1;151(1):133-57.

PMID:
8402925
39.

Rapid Il-2-induced adherence of human natural killer cells. Expression of mRNA for cytokines and IL-2 receptors in adherent NK cells.

Vitolo D, Vujanovic NL, Rabinowich H, Schlesinger M, Herberman RB, Whiteside TL.

J Immunol. 1993 Aug 15;151(4):1926-37.

PMID:
8345189
40.

Monoclonal antibody to a triggering structure expressed on rat natural killer cells and adherent lymphokine-activated killer cells.

Chambers WH, Vujanovic NL, DeLeo AB, Olszowy MW, Herberman RB, Hiserodt JC.

J Exp Med. 1989 Apr 1;169(4):1373-89.

41.
42.

Generation and characterization of purified adherent lymphokine-activated killer cells in mice.

Gunji Y, Vujanovic NL, Hiserodt JC, Herberman RB, Gorelik E.

J Immunol. 1989 Mar 1;142(5):1748-54.

PMID:
2783950
43.

Lymphokine-activated killer cells in rats: generation of natural killer cells and lymphokine-activated killer cells from bone marrow progenitor cells.

Sarneva M, Vujanovic NL, Van den Brink MR, Herberman RB, Hiserodt JC.

Cell Immunol. 1989 Feb;118(2):448-57.

PMID:
2910504
44.

In vivo distribution and tissue localization of highly purified rat lymphokine-activated killer (LAK) cells.

Maghazachi AA, Herberman RB, Vujanovic NL, Hiserodt JC.

Cell Immunol. 1988 Aug;115(1):179-94.

PMID:
3261203
45.

A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells.

Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB.

Cancer Res. 1988 Jun 15;48(12):3461-9.

46.
47.

Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.

Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW, Hiserodt JC.

Cancer Res. 1988 Feb 15;48(4):884-90.

48.
50.

Studies on lymphokine activated killer cells in the rat: analysis of precursor and effector cell phenotype and relationship to natural killer cells.

Hiserodt JC, Vujanovic NL, Reynolds CW, Herberman RB, Cramer DV.

Prog Clin Biol Res. 1987;244:137-46. No abstract available.

PMID:
2958869

Supplemental Content

Loading ...
Support Center